US 2011/0086898 A1 · PYRAZOLOOXAZOLE COMPOUND

Abstract

A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism. wherein R1 and R2 are the same or different and are a hydrogen atom, a C1-6 alkyl group, a cyclic group selected from a C3-6 cycloalkyl group, a tetrahydropyranyl group, a dihydropyranyl group, a tetrahydrofuryl group, a dioxanyl group, a tetrahydrothienyl group, a dithianyl group and a hexahydrothiepinyl group, a C1-6 alkyl group substituted with a cyclic group selected from a C3-6 cycloalkyl group, a tetrahydropyranyl group, a dihydropyranyl group, a tetrahydrofuryl group, a dioxanyl group, a tetrahydrothienyl group, a dithianyl group and a hexahydrothiepinyl group, etc; R3, R4 and R5 are the same or different and are a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C1-6 alkoxy-C1-6 alkyl group, a C3-6 cycloalkoxy-C1-6 alkyl group or a halogen atom; R6 is a hydrogen atom or a C1-6 alkyl group; and R7 is a C1-6 alkyl group, a C1-6 alkoxy group or a C1-6 alkylthio group.

Claims18

Dependent claims

A compound represented by the formula (I) or pharmacologically acceptable salt thereof:

wherein R1 and R2 are the same or different and are (a) a hydrogen atom, (b) a C1-6 alkyl group, (c) a cyclic group selected from a C3-6 cycloalkyl group, a tetrahydropyranyl group, a dihydropyranyl group, a tetrahydrofuryl group, a dioxanyl group, a tetrahydrothienyl group, a dithianyl group and a hexahydrothiepinyl group, (d) a C1-6 alkyl group substituted with a cyclic group selected from a C3-6 cycloalkyl group, a tetrahydropyranyl group, a dihydropyranyl group, a tetrahydrofuryl group, a dioxanyl group, a tetrahydrothienyl group, a dithianyl group and a hexahydrothiepinyl group or (e) R1 and R2, together with a nitrogen atom to which they are attached, form a pyrrolidinyl group, a piperidinyl group or a morpholinyl group;
R3, R4 and R5 are the same or different and are a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C1-6 alkoxy-C1-6 alkyl group, a C3-6 cycloalkoxy-C1-6 alkyl group or a halogen atom;
R6 is a hydrogen atom or a C1-6 alkyl group;
and
R7 is a C1-6 alkyl group, a C1-6 alkoxy group or a C1-6 alkylthio group.

2 more elements

A compound represented by the formula (Ia) or pharmacologically acceptable salt thereof:

wherein R1x and R2x are the same or different and are (a) a C1-6 alkyl group, (b) a cyclic group selected from a C3-6 cycloalkyl group, a tetrahydropyranyl group, a dihydropyranyl group, a tetrahydrofuryl group, a dioxanyl group, a tetrahydrothienyl group, a dithianyl group and a hexahydrothiepinyl group, (c) a C1-6 alkyl group substituted with a cyclic group selected from a C3-6 cycloalkyl group, a tetrahydropyranyl group, a dihydropyranyl group, a tetrahydrofuryl group, a dioxanyl group, a tetrahydrothienyl group, a dithianyl group and a hexahydrothiepinyl group or (d) R1x and R2x, together with a nitrogen atom to which they are attached, form a pyrrolidinyl group, a piperidinyl group or a morpholinyl group;
R3x, R4x and R5x are the same or deferent and are a hydrogen atom, a C1-6 alkyl group, C3-6 cycloalkyl, a C1-6 alkoxy group, a C1-6 alkoxy-C1-6 alkyl group, a C3-6 cycloalkoxy-C1-6 alkyl group or a halogen atom;
R6x is a hydrogen atom or a C1-6 alkyl group;
and
R7x is a C1-6 alkyl group, a C1-6 alkoxy group or a C1-6 alkylthio group,
with the proviso that when R7x is a C1-6 alkyl group, at least one of R1x and R2x is (a) a cyclic group selected from a tetrahydropyranyl group, a dihydropyranyl group, a tetrahydrofuryl group and a dioxanyl group or (b) a C1-6 alkyl group substituted with a cyclic group selected from a tetrahydropyranyl group, a dihydropyranyl group, a tetrahydrofuryl group and a dioxanyl group.

3 more elements

Dependencies are inferred from the claim text.

Pyrazolooxazole compound

Life of this patent

Pyrazolooxazole compound

Life of this patent

Abstract

Claims18